Anaphylaxis from filgrastim prophylaxis within the same day of chemotherapy: A case report
Introduction: Filgrastim is recommended to be used 24–72 h after the last dose of chemotherapy for the prophylaxis of febrile neutropenia. However, several studies demonstrate the efficacy and safety of the use of filgrastim within the same day of the last dose of chemotherapy. Case presentation: We...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Current Problems in Cancer: Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621924000504 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846145897460662272 |
|---|---|
| author | Suluck Soontaros Supaporn Wongduang Nattawut Leelakanok |
| author_facet | Suluck Soontaros Supaporn Wongduang Nattawut Leelakanok |
| author_sort | Suluck Soontaros |
| collection | DOAJ |
| description | Introduction: Filgrastim is recommended to be used 24–72 h after the last dose of chemotherapy for the prophylaxis of febrile neutropenia. However, several studies demonstrate the efficacy and safety of the use of filgrastim within the same day of the last dose of chemotherapy. Case presentation: We presented a patient with state IIIC immature teratoma at her right ovary who was treated with the BEP regimen. She received 10 doses of filgrastim per BEP cycle to prevent febrile neutropenia. On the first BEP cycle, the first dose of filgrastim was used within 24 h after the last chemotherapy dose and dyspnea was developed. On the second cycle of BEP, filgrastim was still used as the same-day regimen. One hour after the first dose of filgrastim, anaphylaxis occurred and the patient was treated appropriately. The second dose of filgrastim can be rechallenged successfully and filgrastim can be finished without any adverse events. On the third and fourth cycles of BEP, filgrastim was used as the next-day regimen (interval longer than 24 h). There were no adverse events that occurred during the use of filgrastim. Conclusion: The residual chemotherapy may increase the risk of anaphylaxis induced by filgrastim via a non-IgE-mediated mechanism in this case patient. |
| format | Article |
| id | doaj-art-969a4e4523e04fcc942b5644abe185ff |
| institution | Kabale University |
| issn | 2666-6219 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Current Problems in Cancer: Case Reports |
| spelling | doaj-art-969a4e4523e04fcc942b5644abe185ff2024-12-02T05:06:49ZengElsevierCurrent Problems in Cancer: Case Reports2666-62192024-12-0116100328Anaphylaxis from filgrastim prophylaxis within the same day of chemotherapy: A case reportSuluck Soontaros0Supaporn Wongduang1Nattawut Leelakanok2Department of Pharmacy, Chonburi Hospital, Chonburi 20000, ThailandDepartment of Pharmacy, Chonburi Hospital, Chonburi 20000, ThailandDivision of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Burapha University, Chonburi 20131, Thailand; Corresponding author.Introduction: Filgrastim is recommended to be used 24–72 h after the last dose of chemotherapy for the prophylaxis of febrile neutropenia. However, several studies demonstrate the efficacy and safety of the use of filgrastim within the same day of the last dose of chemotherapy. Case presentation: We presented a patient with state IIIC immature teratoma at her right ovary who was treated with the BEP regimen. She received 10 doses of filgrastim per BEP cycle to prevent febrile neutropenia. On the first BEP cycle, the first dose of filgrastim was used within 24 h after the last chemotherapy dose and dyspnea was developed. On the second cycle of BEP, filgrastim was still used as the same-day regimen. One hour after the first dose of filgrastim, anaphylaxis occurred and the patient was treated appropriately. The second dose of filgrastim can be rechallenged successfully and filgrastim can be finished without any adverse events. On the third and fourth cycles of BEP, filgrastim was used as the next-day regimen (interval longer than 24 h). There were no adverse events that occurred during the use of filgrastim. Conclusion: The residual chemotherapy may increase the risk of anaphylaxis induced by filgrastim via a non-IgE-mediated mechanism in this case patient.http://www.sciencedirect.com/science/article/pii/S2666621924000504AnaphylaxisCase reportFilgrastimGranulocyte colony-stimulating factorSame day |
| spellingShingle | Suluck Soontaros Supaporn Wongduang Nattawut Leelakanok Anaphylaxis from filgrastim prophylaxis within the same day of chemotherapy: A case report Current Problems in Cancer: Case Reports Anaphylaxis Case report Filgrastim Granulocyte colony-stimulating factor Same day |
| title | Anaphylaxis from filgrastim prophylaxis within the same day of chemotherapy: A case report |
| title_full | Anaphylaxis from filgrastim prophylaxis within the same day of chemotherapy: A case report |
| title_fullStr | Anaphylaxis from filgrastim prophylaxis within the same day of chemotherapy: A case report |
| title_full_unstemmed | Anaphylaxis from filgrastim prophylaxis within the same day of chemotherapy: A case report |
| title_short | Anaphylaxis from filgrastim prophylaxis within the same day of chemotherapy: A case report |
| title_sort | anaphylaxis from filgrastim prophylaxis within the same day of chemotherapy a case report |
| topic | Anaphylaxis Case report Filgrastim Granulocyte colony-stimulating factor Same day |
| url | http://www.sciencedirect.com/science/article/pii/S2666621924000504 |
| work_keys_str_mv | AT sulucksoontaros anaphylaxisfromfilgrastimprophylaxiswithinthesamedayofchemotherapyacasereport AT supapornwongduang anaphylaxisfromfilgrastimprophylaxiswithinthesamedayofchemotherapyacasereport AT nattawutleelakanok anaphylaxisfromfilgrastimprophylaxiswithinthesamedayofchemotherapyacasereport |